|Bid||3.2300 x 900|
|Ask||3.2400 x 800|
|Day's Range||3.1300 - 3.3100|
|52 Week Range||2.1200 - 5.0100|
|Beta (5Y Monthly)||2.35|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Subscribe to Yahoo Finance Plus to view Fair Value for MNMD
NEW YORK, November 02, 2023--MindMed today reported its financial results for the quarter ended September 30, 2023.
NEW YORK, October 26, 2023--MindMed plans to host a conference call on Thursday, November 2, 2023, at 4:30 p.m. ET.
NEW YORK, October 24, 2023--Enrollment completed for MMED007, the Phase 2a study evaluating repeated low-dose administration of MM-120 for the treatment of adults with ADHD.